Synthesis, Structure–Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists

Authors:

Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder which has a higher prevalence and incidence in people older than 60 years. The need for improved AD therapies is unmet as the current therapies are symptomatic with modest efficacy. The 5-HT4 receptor (5-HT4R) partial agonists offer both symptomatic and disease modifying treatment as they shift amyloid precursor protein (APP) processing from amyloidogenic to non-amyloidogenic pathway by activating α-secretase enzyme. In addition, they also offer symptomatic treatment by increasing neurotransmitter acetylcholine levels in the brain. Fascinated by dual mechanism of action, several chemical scaffolds having 5-HT4R pharmacophore were designed and evaluated. Most of the synthesized compounds showed potent in vitro affinities and in vivo efficacies. Upon focused structure activity relationships, compound 4o was identified as potent 5-HT4R partial agonist with favorable ADME properties and good in vivo efficacy. GR-125487, a selective 5-HT4R antagonist attenuated the activity of compound 4o in cognition model NORT.

This publication has 38 references indexed in Scilit: